The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus
© 2021. The Author(s)..
INTRODUCTION: Treatment-related quality of life (QOL) is an important aspect of diabetes management. We evaluated the influence of a sodium-glucose cotransporter 2 (SGLT2) inhibitor, tofogliflozin, on treatment-related QOL in Japanese patients with type 2 diabetes mellitus (T2DM).
METHODS: This is the prespecified subanalysis study of the "Using TOfogliflozin for Possible better Intervention against Atherosclerosis for type 2 diabetes patients (UTOPIA)" trial. Treatment-related QOL was evaluated at baseline, week 26, week 52, and week 104 after the initiation of the study using the Diabetes Therapy-Related QOL questionnaire (DTR-QOL). Among the 340 patients in the original UTOPIA study, a total of 252 patients (127, tofogliflozin group; 125, conventional treatment group) who completed the DTR-QOL questionnaire at baseline were the study subjects of the current subanalysis.
RESULTS: The tofogliflozin and conventional treatment groups exhibited almost comparable baseline clinical characteristics, while the use of antihypertensive drugs and lipid-lowering agents was significantly lower in the tofogliflozin treatment group than in the conventional treatment group. Tofogliflozin treatment increased the total score of DTR-QOL7 from baseline (P < 0.001), while conventional treatment did not change it. There were statistically significant differences in delta change in the total DTR-QOL7 score and DTR-QOL7 Q4, Q5, Q6, and Q7 scores from the baseline to week 104 between the treatment groups. Delta changes in HbA1c (Spearman's correlation coefficient, ρ = - 0.30, P < 0.001), fasting blood glucose (ρ = - 0.16, P = 0.031), BMI (ρ = - 0.19, P = 0.008), and waist circumference (ρ = - 0.17, P = 0.024) at week 104 were negatively associated with delta change in the total QOL7 score.
CONCLUSIONS: Our data indicated that tofogliflozin treatment improved treatment-related QOL compared to conventional treatment in Japanese patients with T2DM, in accordance with the improvement of major cardiovascular risk factors.
TRIAL REGISTRATION: UMIN000017607.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Diabetes therapy : research, treatment and education of diabetes and related disorders - 12(2021), 9 vom: 06. Sept., Seite 2499-2515 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Katakami, Naoto [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Revised 10.09.2021 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s13300-021-01125-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329018493 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329018493 | ||
| 003 | DE-627 | ||
| 005 | 20231226203414.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13300-021-01125-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1096.xml |
| 035 | |a (DE-627)NLM329018493 | ||
| 035 | |a (NLM)34357559 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Katakami, Naoto |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.09.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a INTRODUCTION: Treatment-related quality of life (QOL) is an important aspect of diabetes management. We evaluated the influence of a sodium-glucose cotransporter 2 (SGLT2) inhibitor, tofogliflozin, on treatment-related QOL in Japanese patients with type 2 diabetes mellitus (T2DM) | ||
| 520 | |a METHODS: This is the prespecified subanalysis study of the "Using TOfogliflozin for Possible better Intervention against Atherosclerosis for type 2 diabetes patients (UTOPIA)" trial. Treatment-related QOL was evaluated at baseline, week 26, week 52, and week 104 after the initiation of the study using the Diabetes Therapy-Related QOL questionnaire (DTR-QOL). Among the 340 patients in the original UTOPIA study, a total of 252 patients (127, tofogliflozin group; 125, conventional treatment group) who completed the DTR-QOL questionnaire at baseline were the study subjects of the current subanalysis | ||
| 520 | |a RESULTS: The tofogliflozin and conventional treatment groups exhibited almost comparable baseline clinical characteristics, while the use of antihypertensive drugs and lipid-lowering agents was significantly lower in the tofogliflozin treatment group than in the conventional treatment group. Tofogliflozin treatment increased the total score of DTR-QOL7 from baseline (P < 0.001), while conventional treatment did not change it. There were statistically significant differences in delta change in the total DTR-QOL7 score and DTR-QOL7 Q4, Q5, Q6, and Q7 scores from the baseline to week 104 between the treatment groups. Delta changes in HbA1c (Spearman's correlation coefficient, ρ = - 0.30, P < 0.001), fasting blood glucose (ρ = - 0.16, P = 0.031), BMI (ρ = - 0.19, P = 0.008), and waist circumference (ρ = - 0.17, P = 0.024) at week 104 were negatively associated with delta change in the total QOL7 score | ||
| 520 | |a CONCLUSIONS: Our data indicated that tofogliflozin treatment improved treatment-related QOL compared to conventional treatment in Japanese patients with T2DM, in accordance with the improvement of major cardiovascular risk factors | ||
| 520 | |a TRIAL REGISTRATION: UMIN000017607 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Quality of life (QOL) | |
| 650 | 4 | |a Sodium-glucose cotransporter 2 (SGLT2) inhibitor | |
| 650 | 4 | |a Tofogliflozin | |
| 650 | 4 | |a Type 2 diabetes mellitus | |
| 700 | 1 | |a Mita, Tomoya |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshii, Hidenori |e verfasserin |4 aut | |
| 700 | 1 | |a Shiraiwa, Toshihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Yasuda, Tetsuyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Okada, Yosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Torimoto, Keiichi |e verfasserin |4 aut | |
| 700 | 1 | |a Umayahara, Yutaka |e verfasserin |4 aut | |
| 700 | 1 | |a Kaneto, Hideaki |e verfasserin |4 aut | |
| 700 | 1 | |a Osonoi, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Tsunehiko |e verfasserin |4 aut | |
| 700 | 1 | |a Kuribayashi, Nobuichi |e verfasserin |4 aut | |
| 700 | 1 | |a Maeda, Kazuhisa |e verfasserin |4 aut | |
| 700 | 1 | |a Yokoyama, Hiroki |e verfasserin |4 aut | |
| 700 | 1 | |a Kosugi, Keisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Ohtoshi, Kentaro |e verfasserin |4 aut | |
| 700 | 1 | |a Hayashi, Isao |e verfasserin |4 aut | |
| 700 | 1 | |a Sumitani, Satoru |e verfasserin |4 aut | |
| 700 | 1 | |a Tsugawa, Mamiko |e verfasserin |4 aut | |
| 700 | 1 | |a Ryomoto, Kayoko |e verfasserin |4 aut | |
| 700 | 1 | |a Taki, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamura, Tadashi |e verfasserin |4 aut | |
| 700 | 1 | |a Kawashima, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Yasunori |e verfasserin |4 aut | |
| 700 | 1 | |a Watada, Hirotaka |e verfasserin |4 aut | |
| 700 | 1 | |a Shimomura, Iichiro |e verfasserin |4 aut | |
| 700 | 0 | |a UTOPIA study investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Hayashi, I |e investigator |4 oth | |
| 700 | 1 | |a Tsugawa, M |e investigator |4 oth | |
| 700 | 1 | |a Yokoyama, H |e investigator |4 oth | |
| 700 | 1 | |a Yoshii, H |e investigator |4 oth | |
| 700 | 1 | |a Komiyama, K |e investigator |4 oth | |
| 700 | 1 | |a Mita, T |e investigator |4 oth | |
| 700 | 1 | |a Shimizu, T |e investigator |4 oth | |
| 700 | 1 | |a Yamamoto, T |e investigator |4 oth | |
| 700 | 1 | |a Kawashima, S |e investigator |4 oth | |
| 700 | 1 | |a Nakamura, T |e investigator |4 oth | |
| 700 | 1 | |a Kamei, S |e investigator |4 oth | |
| 700 | 1 | |a Kinoshita, T |e investigator |4 oth | |
| 700 | 1 | |a Shimoda, M |e investigator |4 oth | |
| 700 | 1 | |a Maeda, K |e investigator |4 oth | |
| 700 | 1 | |a Kosugi, K |e investigator |4 oth | |
| 700 | 1 | |a Yoshii, H |e investigator |4 oth | |
| 700 | 1 | |a Ishida, H |e investigator |4 oth | |
| 700 | 1 | |a Osonoi, T |e investigator |4 oth | |
| 700 | 1 | |a Saito, M |e investigator |4 oth | |
| 700 | 1 | |a Tamazawa, A |e investigator |4 oth | |
| 700 | 1 | |a Sumitani, S |e investigator |4 oth | |
| 700 | 1 | |a Fujiki, N |e investigator |4 oth | |
| 700 | 1 | |a Fujita, Y |e investigator |4 oth | |
| 700 | 1 | |a Shimizu, S |e investigator |4 oth | |
| 700 | 1 | |a Umayahara, Y |e investigator |4 oth | |
| 700 | 1 | |a Kato, K |e investigator |4 oth | |
| 700 | 1 | |a Irie, Y |e investigator |4 oth | |
| 700 | 1 | |a Kataoka, R |e investigator |4 oth | |
| 700 | 1 | |a Yasuda, T |e investigator |4 oth | |
| 700 | 1 | |a Kiyohara, Y |e investigator |4 oth | |
| 700 | 1 | |a Ohashi, M |e investigator |4 oth | |
| 700 | 1 | |a Ryomoto, K |e investigator |4 oth | |
| 700 | 1 | |a Takahi, Y |e investigator |4 oth | |
| 700 | 1 | |a Fujishima, Y |e investigator |4 oth | |
| 700 | 1 | |a Fujita, Y |e investigator |4 oth | |
| 700 | 1 | |a Fukuhara, A |e investigator |4 oth | |
| 700 | 1 | |a Fukui, K |e investigator |4 oth | |
| 700 | 1 | |a Hosokawa, Y |e investigator |4 oth | |
| 700 | 1 | |a Imagawa, A |e investigator |4 oth | |
| 700 | 1 | |a Iwahashi, H |e investigator |4 oth | |
| 700 | 1 | |a Mukai, K |e investigator |4 oth | |
| 700 | 1 | |a Katakami, N |e investigator |4 oth | |
| 700 | 1 | |a Katsura, T |e investigator |4 oth | |
| 700 | 1 | |a Kawamori, D |e investigator |4 oth | |
| 700 | 1 | |a Kimura, T |e investigator |4 oth | |
| 700 | 1 | |a Kobayashi, S |e investigator |4 oth | |
| 700 | 1 | |a Kozawa, J |e investigator |4 oth | |
| 700 | 1 | |a Kubo, F |e investigator |4 oth | |
| 700 | 1 | |a Maeda, N |e investigator |4 oth | |
| 700 | 1 | |a Matsuoka, T |e investigator |4 oth | |
| 700 | 1 | |a Miyashita, K |e investigator |4 oth | |
| 700 | 1 | |a Nakata, S |e investigator |4 oth | |
| 700 | 1 | |a Ninomiya, H |e investigator |4 oth | |
| 700 | 1 | |a Nishizawa, H |e investigator |4 oth | |
| 700 | 1 | |a Okuno, Y |e investigator |4 oth | |
| 700 | 1 | |a Otsuki, M |e investigator |4 oth | |
| 700 | 1 | |a Sakamoto, F |e investigator |4 oth | |
| 700 | 1 | |a Sasaki, S |e investigator |4 oth | |
| 700 | 1 | |a Sato, I |e investigator |4 oth | |
| 700 | 1 | |a Shimo, N |e investigator |4 oth | |
| 700 | 1 | |a Shimomura, I |e investigator |4 oth | |
| 700 | 1 | |a Takahara, M |e investigator |4 oth | |
| 700 | 1 | |a Takano, T |e investigator |4 oth | |
| 700 | 1 | |a Tokunaga, A |e investigator |4 oth | |
| 700 | 1 | |a Uno, S |e investigator |4 oth | |
| 700 | 1 | |a Yamaoka, M |e investigator |4 oth | |
| 700 | 1 | |a Yoneda, S |e investigator |4 oth | |
| 700 | 1 | |a Ohtoshi, K |e investigator |4 oth | |
| 700 | 1 | |a Shiraiwa, T |e investigator |4 oth | |
| 700 | 1 | |a Hajime, M |e investigator |4 oth | |
| 700 | 1 | |a Koikawa, K |e investigator |4 oth | |
| 700 | 1 | |a Kuno, F |e investigator |4 oth | |
| 700 | 1 | |a Kurozumi, A |e investigator |4 oth | |
| 700 | 1 | |a Matsushita, K |e investigator |4 oth | |
| 700 | 1 | |a Narisawa, M |e investigator |4 oth | |
| 700 | 1 | |a Tanaka, K |e investigator |4 oth | |
| 700 | 1 | |a Sugai, K |e investigator |4 oth | |
| 700 | 1 | |a Okada, Y |e investigator |4 oth | |
| 700 | 1 | |a Torimoto, K |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes therapy : research, treatment and education of diabetes and related disorders |d 2012 |g 12(2021), 9 vom: 06. Sept., Seite 2499-2515 |w (DE-627)NLM215796888 |x 1869-6953 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |g number:9 |g day:06 |g month:09 |g pages:2499-2515 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s13300-021-01125-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 |e 9 |b 06 |c 09 |h 2499-2515 | ||